MG
ORMP icon

Mather Group’s Oramed Pharmaceuticals ORMP Stock Holding History

Mather Group’s Portfolio ORMP Stock Details ORMP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-100
Closed -$292 – 2046
2024
Q2 		$292 Buy
+100
New +$238 ﹤0.01% 2107

Other funds holding ORMP

BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
M
Murchinson Toronto, Ontario, Canada $791M AUM 68.08% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
RG
Rathbones Group Liverpool, United Kingdom $25B AUM 18.87% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $43.4B AUM 51.29% 1-Year Est. Return

Mather Group's ORMP Position: Q3 2024 in Review

Mather Group sold out of Oramed Pharmaceuticals (ORMP) in Q3 2024, closing a stake of 100 shares — an estimated $292 sold.

Mather Group first reported a position in ORMP in Q2 2024 and held it in 1 quarter. The position peaked at $292 in Q2 2024. 55 funds tracked by Wall St. Rank hold ORMP as of Q3 2024.

  • Mather Group reported no remaining Oramed Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
  • Mather Group sold 100 Oramed Pharmaceuticals shares in Q3 2024, an estimated $292.
  • Mather Group first reported a position in Oramed Pharmaceuticals in Q2 2024 and held it in 1 quarter.
  • Mather Group's Oramed Pharmaceuticals position peaked at $292 in Q2 2024.
  • 55 funds tracked by Wall St. Rank held Oramed Pharmaceuticals as of Q3 2024.

Based on Mather Group's 13F filing for Q3 2024, filed 7 Oct 2024.